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Abstract
Background: Preterm birth is the leading cause of perinatal morbidity and mortality. Risk factors for preterm birth
include a personal or familial history of preterm delivery, ethnicity and low socioeconomic status yet the ability to
predict preterm delivery before the onset of preterm labour evades clinical practice. Evidence suggests that
genetics may play a role in the multi-factorial pathophysiology of preterm birth. The All Our Babies Study is an
on-going community based longitudinal cohort study that was designed to establish a cohort of women to
investigate how a women’s genetics and environment contribute to the pathophysiology of preterm birth.
Specifically this study will examine the predictive potential of maternal leukocytes for predicting preterm birth in
non-labouring women through the examination of gene expression profiles and gene-environment interactions.
Methods/Design: Collaborations have been established between clinical lab services, the provincial health service
provider and researchers to create an interdisciplinary study design for the All Our Babies Study. A birth cohort of
2000 women has been established to address this research question. Women provide informed consent for blood
sample collection, linkage to medical records and complete questionnaires related to prenatal health, service
utilization, social support, emotional and physical health, demographics, and breast and infant feeding. Maternal
blood samples are collected in PAXgene™ RNA tubes between 18-22 and 28-32 weeks gestation for transcriptomic
analyses.
Discussion: The All Our Babies Study is an example of how investment in clinical-academic-community
partnerships can improve research efficiency and accelerate the recruitment and data collection phases of a study.
Establishing these partnerships during the study design phase and maintaining these relationships through the
duration of the study provides the unique opportunity to investigate the multi-causal factors of preterm birth. The
overall All Our Babies Study results can potentially lead to healthier pregnancies, mothers, infants and children.
Background
Preterm birth remains poorly understood in modern
society despite accounting for 75% of perinatal mortality
[1,2]. Moreover, the rate of preterm birth, that is birth
before 37 completed weeks of gestation, has been on the
rise for the past 3 decades in many developed countries
including Canada, the USA and European nations where
current rates range between 5-12% [3]. Infants born pre-
term are at increased risks for neonatal complications
and associated long-term morbidity [4] such as develop-
mental delays, hearing and vision impairments, respira-
tory distress syndrome, cerebral palsy and retinopathy of
prematurity, prolonging the financial, emotional and
stress-related costs of prematurity well beyond the care
received within neonatal intensive care units. The risk
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gestational age at birth with the highest morbidity
among those infants delivered prior to 28 completed
weeks of pregnancy (early preterm) [5] despite technolo-
gical advances and improved medical treatments having
greatly increased the survival of these infants [6,7]. The
rate of late preterm births (34-36 weeks gestation) has
also continued to climb and accounts for 75% of all pre-
term infants [8]. Recent studies have shown that these
late preterm infants are at higher risk for adverse acute
and long-term outcomes when compared to term
infants [9].
The pathophysiology of preterm birth is complex due
to multi-factorial causes and its heterogeneous nature.
Preterm birth is often categorized as (1) iatrogenic when
delivery is a consequence of medical intervention (30-
35%); (2) spontaneous when it occurs after spontaneous
labour with intact membranes (40-45%); or (3) the result
of preterm premature rupture of the membranes
(PPROM) (25-30%) [3]. While gestational diabetes, pree-
clampsia and intrauterine growth restriction have all
been associated with iatrogenic preterm birth, the
underlying causes of spontaneous preterm birth are
less clear. Reported risk factors are widespread and
diverse, supporting the hypothesis of gene-gene and
gene-environment interactions in the pathophysiology of
spontaneous preterm birth. Highly associated risk fac-
tors include a previous preterm birth or a relative with
preterm birth [10] or a black racial background [11],
suggesting genetic causes. Other demographic factors
such as low socioeconomic status [12] and maternal
stress [13] have shown an association, indicating that
the environment contributes to the etiology of sponta-
neous preterm birth.
Evidence for a causal role of infection and inflamma-
tion in preterm birth has been reviewed in detail [14].
Both interleukin (IL)-1b and tumor necrosis factor
(TNF)a are cytokines produced by the intrauterine tis-
sues in response to bacterial infections [15,16] which sti-
mulate prostaglandin synthesis [17] and increase uterine
contractility. Several groups have investigated the rela-
tionship between a single nucleotide polymorphism
(SNP) located in the promoter of the TNFa gene
(G-308>A) (referred to as the TNF-2 allele) and preterm
birth, but inconsistent results have been reported
[18-21]. A recent meta-analysis of seven studies [22]
found no association between preterm parturition and
the TNF-2 allele. Similarly, studies examining poly-
morphisms in IL-1b and IL-6 as well as other variants
have also produced inconsistent results [19,23,24].
These inconsistencies may be the result of gene-
environment interactions impacting the effects of poten-
tial genetic predispositions to preterm birth. For
example, Macones et al. reported an increased risk of
preterm delivery being associated with both the TNF-2
allele and the presence of bacterial vaginosis, but not with
either factor alone [25] suggesting a synergistic interaction.
These findings highlight the complexity of understanding
preterm birth and the need for an interdisciplinary
approach, a strategy embraced by the Preterm Birth Inter-
national Collaborative (PREBIC) in recently published
guidelines for preterm birth research [26].
Prediction of risk for preterm birth is critical to suc-
cessful clinical management. Understanding risk and
protective factors is best accomplished through the
development of a pregnancy cohort where asymptomatic
women can be prospectively recruited and followed over
time. Despite our growing awareness that infection,
inflammation, stress and other risk factors contribute to
the pathophysiology of preterm birth, predicting which
women will deliver preterm remains an ongoing chal-
lenge. Many biomarkers for preterm birth have been
suggested and explored such as fetal fibronectin [27,28],
maternal corticotropin releasing hormone (CRH) [29],
and cervical length [30] however all have had limitations
such as low positive predictive values, low sensitivity or
poor specificity [31] in addition to high inter-individual
variability, which limit their translation into clinical set-
tings. Bocking et al. have shown that white blood cell
(leukocyte) counts [32] or the presence of infection [33]
at 22-27 weeks gestation is an accurate predictor of pre-
term birth before 28 weeks gestation. These researchers
have also shown CRH or combination of CRH and
m a t e r n a la g et ob ep r e d i c t i v ef o rm i dt ol a t ep r e t e r m
deliveries respectively. Recent multiple-marker tests for
risk of preterm birth show promise but continue to have
limited predictive power for non-labouring women [34].
A clinical screen for risk of preterm delivery before
women have signs or symptoms of preterm labour is
needed. The evidence also suggests that an interdisci-
plinary approach is required to understand preterm
birth pathophysiology. The purpose of this paper is to
describe the methodology for community based recruit-
ment of a pregnancy cohort, The All Our Babies Cohort
Study, to examine genetic, environmental and pathophy-
siologic contributions to preterm birth.
Methods/Design
Objectives
The aims of the All Our Babies Cohort Study are
a) To investigate genetic components of preterm
birth through comparisons of transcriptomic pat-
terns at 18-22 weeks and 28-32 weeks of pregnancy
between spontaneous preterm birth cases and term
delivering controls,
b) To examine the association between environmen-
tal factors and preterm birth, including access to
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mental and psychosocial health during pregnancy,
and;
c) To examine the relative impact of genes and
environment on the risk of preterm birth by explor-
ing the interactions between medical history, gene
expression patterns and environmental variables.
Study Design
The All Our Babies Cohort Study is a community-based
prospective pregnancy cohort study to determine the
environmental and genetic risks for preterm birth.
Study Population
The study population is drawn from all women who
receive prenatal viral serology testing in Calgary,
Alberta, Canada. Participants reside within the Calgary
city limits and surrounding rural communities. Women
are recruited through a partnership with the clinical
laboratory service in Calgary.
Inclusion Criteria
Inclusion criteria for the All Our Babies Cohort Study
are designed to ensure women most at risk of preterm
birth are captured in the cohort.
1. Women <17 weeks 6 days gestation at time of
recruitment
2. Women receiving prenatal care in Calgary
3. Women able to understand written and spoken
English
4. Age 18 years or older at time of enrollment
5. One of the following pregnancy histories:
a. Nulliparous or primiparous OR
b. A personal or familial history of preterm birth
6. Singleton pregnancy
Exclusion Criteria
1. Planned to move outside of the greater Calgary
area during their pregnancy
2. Known to be carrying multiples at the time of
enrollment
3. Had any of the following pre-existing medical
conditions
a. Type I or Type II diabetes
b. High blood pressure or hypertension
c. Autoimmune/immune disorders: lupus, rheu-
matoid arthritis, Sjogren’s syndrome
d. Kidney disease, chronic renal disease, nephri-
tis, nephropathy, dialysis
e. A heart problem that was repaired by surgery
f. Chronic infection: hepatitis, HIV
Recruitment Strategies
Prenatal clinical practice guidelines prompt evaluation of
viral serology by public health laboratories. The sole
provider of phlebotomy for this service in the Calgary
region is Calgary Laboratory Service. Women with
laboratory orders for prenatal viral serology tests are
contacted by telephone by the clinical laboratory to ask
for permission to release their contact information to
the research staff. Women that consent to the release of
their information are subsequently contacted by tele-
phone to determine eligibility, inform them about the
study and invite them to participate. Women who pro-
vide verbal consent to participate are enrolled in the
study and are mailed a record of the consent form for
their records. Written consent for blood collections and
associated genetic analyses is obtained at the time of the
first blood collection and prior to the blood draw.
Questionnaire Data Collection
Questionnaires were developed to address the objectives
of the All Our Babies Cohort Study and included input
from academics, stakeholders and decision makers.
These questionnaires (available on request) assess demo-
graphics, pregnancy history, service utilization, nutrition
and exercise practices, mental health, social support,
lifestyle and life history, and breastfeeding experiences
through questions designed for this study as well as the
following validated instruments: Edinburgh Postnatal
Depression Scale [35], Spielberger State Anxiety Scale
[36], MOS Social Support Scale [37], Perceived Stress
Scale [38], T-ACE Screen for alcohol consumption risk
[39], Parenting Morale Index [40], the Parental Expecta-
tions Scale for parenting self-efficacy [41], and the MCH
Feeding Scale (personal communication, M. Ramsay,
Feeding Problem Questionnaire 2003). The question-
naires were pilot tested prior to study commencement
and revised for unclear wording. The questionnaires
were designed using the Cardiff Teleform software suite
(Cardiff Teleform, Version 10.1, 2007) which enables the
conversion to electronic data upon completion of paper-
based copies.
The first questionnaire is mailed out at study enroll-
ment for completion before 24 weeks of gestation.
Women are given reminder calls beginning at 20 weeks
gestation or 3 weeks after the questionnaire is mailed,
whichever is later, to answer participants’ questions and
encourage completion and return of the questionnaire.
The second questionnaire is mailed to all participants
at 32 weeks gestation, to be completed between 34-36
weeks gestation. At 36 weeks gestation, women are con-
tacted by telephone to provide a reminder about the
questionnaire. A modified version of this questionnaire
is used for women who delivered prior to receiving or
completing the questionnaire.
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four months post-partum. Women are contacted two
weeks after their expected due date to determine the
birthdate of their infant(s). The questionnaire is mailed
to participants at 3.5 months postpartum.
Obstetrical and Birth Record Data
The Alberta Perinatal Health (APH) database is an
Alberta-based database that contains prenatal maternal
and birth outcome information from all recorded births
in the province. Study participants provide informed
consent to access medical records. This enables the
questionnaire data to be linked to their APH adminis-
trative data about birth outcomes, and to examine medi-
cal records to verify circumstances associated with
preterm birth.
Due to the expected 18 month delay to populate and
validate the APH database, study team members per-
form manual chart extractions for all preterm deliveries
in the All Our Babies Cohort Study. This accelerates the
collection of key medical record variables and is
required to phenotype each preterm birth and enable
case selection for the genetic analyses.
Maternal Blood Specimens
Maternal blood samples are collected at 18-22 weeks
gestation and at 28-32 weeks gestation either at a
laboratory location or by a mobile phlebotomist. Partici-
pants are contacted at 17 and 27 weeks gestation by tel-
ephone and/or email to begin scheduling their first and
second blood collections respectively. Collections can
occur at any time of day and fasting is not required.
Four PAXgene™ blood RNA tubes (PreAnalytix/BD
Canada, Mississauga, Ontario, Canada) are used at each
blood collection. These tubes are specially designed to
preserve RNA in whole blood at the time of collection.
Blood is also collected into a heparin tube to isolate
plasma (first collection), a serum collection tube (second
collection) and into an EDTA tube for maternal DNA
extraction.
Cord Blood Specimens
Umbilical cord blood (3-5 ml) is routinely collected fol-
lowing hospital births to establish infant red blood cell
antigens. Study participants provide informed consent to
allow the researchers to access the unused portion of
these blood specimens that would otherwise be dis-
carded. These samples are stored at -80°C as a source of
fetal DNA.
Summary of Frequency and Duration of Follow-Up
All participants are asked to complete three question-
naires: at <24 weeks gestation, at 34-36 weeks gesta-
tion and at 4 months post-partum for the All Our
Babies Cohort Study. Blood collections are completed
between 18-22 weeks of pregnancy and between 28-32
weeks of pregnancy. Women are contacted at approxi-
mately two weeks after their estimated due date to
determine the delivery date. It is anticipated that parti-
cipants of the All Our Babies Cohort Study will be fol-
lowed-up every two to three years to provide the
opportunity for life course research on maternal, child
and family outcomes.
Methods of Protecting Against Sources of Bias
All women who receive prenatal viral serology phlebot-
omy by Calgary Laboratory Service and consent to be
contacted by researchers are contacted via telephone.
Should they meet the inclusion criteria, the women are
invited to participate in the All Our Babies Cohort
Study. This recruitment strategy minimizes selection
bias due to self-referral or patient populations at specific
clinical practices and enables a citywide and surround-
ing area sampling approach.
Questionnaire data is collected prospectively, eliminat-
ing the influence of birth outcome on responses and
potential for differential recall bias. However, the repeat
use of standardized scales may introduce a form of bias
where women remember answering the questions before
and past answers influence responses on subsequent
questionnaires. We anticipate that misclassification
errors in exposure data will not be an issue in the infor-
mation collected and generated from this cohort due to
well-spaced and timely use of questionnaires.
Blood collections are offered at both a permanent
laboratory location and by mobile phlebotomists to
ensure that women are able to provide the blood sample
at a location and time that is comfortable and conveni-
ent. The mobile phlebotomist option enables evening
and weekend blood collections so that work hours are
not a constraint. The flexibility of the blood collection
options minimizes participant loss due to inconvenience
or personal schedule demands.
Proposed Outcome Measures
a) Transcriptomic profiles from maternal blood sam-
ples collected at 18-22 weeks and 28-32 weeks of
pregnancy will be compared between two groups
(women who deliver at term and women who deliver
preterm) for patterns predictive of preterm birth.
b) Health service utilization, maternal social support,
psychosocial well-being, mental health, breastfeeding
and parenting support at four months postpartum
will be compared between term and preterm
deliveries.
c) The relative contribution of the environmental
risk and the genetic risk will be compared between
term and preterm deliveries.
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Sample size calculations for the All Our Babies Cohort
Study required complex considerations as maternal
blood samples are destined for microarray analyses. Sev-
eral power calculations for microarray methodologies
exist, consequently sample size was determined and
compared with two power calculation approaches. The
first approach uses a two-class comparison model with a
significance level of 0.001, a power of 0.95, one technical
replicate per sample and estimated values of τ
2 +2g
2 =
0.25 and τ
2/g
2 =4( w h e r eτ
2 is the biological variance
within class of log ratios and g
2 is the technical variance
of log ratios); the minimum sample size to identify a
two-fold change in gene expression between classes is
thus 25 patients in each study group [42,43]. An alter-
nate approach is to consider the sample size required to
detect a two-fold change in the expression levels of the
90% and 75% least-variable genes for a given set of false
positive rates and power [42]; using previously published
h u m a nt i s s u em i c r o a r r a yd a t a[ 4 3 ]a n ds e t t i n gt h ef a l s e
positive rates at 0.001 and a power of 0.9, this approach
gave a minimum of 18 and 13 patients in each group to
d e t e c tat w o - f o l dc h a n g ei ne x p r e s s i o nl e v e l sf o rt h e
90% and 75% least-variable genes, respectively. Microar-
rays will be performed on RNA samples collected from
80 cases of spontaneous preterm birth and 80 matched
controls (160 biological replicates) from samples col-
lected at two time points (18-22 weeks and 28-32
weeks): a total of 320 microarrays. This sample size will
allow prediction of:
1) idiopathic PTB (n~40), including
a) idiopathic PTB prior to 32 weeks gestation
(n~13); and
b) idiopathic PTB between 32 and 37 weeks gesta-
tion (n~27);
2) PPROM and PTB (n~40), including
a) PPROM and PTB prior to 32 weeks gestation
(n~13);
b) PPROM and PTB between 32 and 37 weeks
gestation (n~27);
3) spontaneous PTB (n~80), including
a) spontaneous PTB prior to 32 weeks (n~25); and
b) spontaneous PTB between 32 and 37 weeks gesta-
tion (n~55).
Therefore, with a preterm birth rate of 9.1% in
Alberta, an anticipated miscarriage rate of 5% and an
anticipated loss to follow-up rate of 15% based on
experience with other Alberta based cohorts [44], 2200
women will be enrolled in the All Our Babies Cohort
Study. This should ensure 1800 women complete the
study, of which approximately 180 will have preterm
birth outcomes and approximately 120 of these will be
spontaneous with or without PPROM.
The impact of access to routine prenatal care and
health services on maternal variables at four months
postpartum will be compared among the entire cohort.
Although the sample size calculations for the All Our
Babies Cohort Study were derived for the microarray
analysis, the sample size of 1800 women is adequate to
describe differences between groups with respect to
health service utilization, maternal social support, psy-
chosocial well-being, mental health, breastfeeding and
parenting support using logistic regression [45-47].
Planned Recruitment Rate
There are approximately 18,500 live births per year in
Calgary [48]. Recruitment for the All Our Babies Cohort
Study began September 2009 and is targeted for com-
pletion late 2010. The recruitment rate has averaged 36
participants/week through the community laboratory
services and represents approximately 10% of births in
Calgary during this period.
Study Compliance
Strategies used to maintain participant involvement
include reminder phone calls for outstanding question-
naires and providing incentives including public library
gift certificates and grocery gift certificates for com-
pleted questionnaires. Mailing the questionnaires and
providing postage paid envelopes has minimized time
and costs to participants.
The All Our Babies Cohort Study participants are pro-
vided with two options for blood collections. Women
may schedule an appointment through the research
team at a central community laboratory clinic within
Calgary. For participants unable or unwilling to travel to
the laboratory clinic, the research team will send a certi-
fied mobile phlebotomist to the women’s home or other
neutral location of her choice for the blood collections.
In appreciation for their time and commitment to the
study, women are provided with department store gift
certificates at the time of their blood collection.
Umbilical cord blood samples collected at the time of
birth at local hospital births are sent to a single transfu-
sion medicine laboratory location. The research team is
notified of delivery and obtains these specimens after all
clinical testing is completed. Women and their health
care providers therefore do not need to do anything at
the time of delivery for the study. Study team members
need not be present at delivery units.
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The All Our Babies Cohort Study anticipates retaining
85% of women after completion of the first question-
naire and excluding miscarriages. Based on women’s
consent to participate in follow-up studies of 97% and
with dedicated retention strategies, it is anticipated that
no more than 10% of study participants will be lost to
follow-up into the preschool years.
Proposed Type and Frequency of Analysis
Transcriptomic Analysis
RNA will be extracted from samples collected from
identified cases (spontaneous preterm births with or
without PPROM) and controls (term deliveries). Cases
and controls will be ‘loosely matched’ such that each
group has a similar distribution of maternal ages, pre-
pregnancy body mass indexes and smoking status.
Extracted RNA will be aliquoted into three tubes - one
for Agilent RNA quality assessment, one for the tran-
scriptomic microarray, and one for validation of micro-
array findings by real time polymerase chain reaction.
Samples will be run on Affymetrix microarrays in two
batches of 40 cases and 40 controls. All statistical ana-
lyses will be conducted on the full dataset generated
from the microarrays.
Statistical Analysis
Transcriptomic data, medical record data and self-report
questionnaire data will first be analyzed univariately.
Participant characteristics will be assessed and compared
to the pregnant and parenting population in the pro-
vince of Alberta and nationwide across Canada. Should
transcriptomic signatures predictive of preterm delivery
phenotypes be elucidated from the microarray analyses
and validation, gene-environment interactions will be
explored by integrating the transcriptomic data with the
questionnaire and medical record datasets using appro-
priate statistical analytical techniques.
Potential Risks To The Safety of Particiants Involved In
The Study
Medical Risks
Participation in the All Our Babies Cohort Study does
not alter women’s medical care during pregnancy. Parti-
cipants are informed about the routine risks during
phlebotomy (eg. risk of bruising or infection). There are
also no direct medical benefits to the participants nor
their infants for participating in the All Our Babies
Cohort Study.
Confidentiality
A coded study ID is assigned to each participant at the
time of enrollment. This ID is used to identify all ques-
tionnaire data, biological specimens and extracted infor-
mation from participants’ medical records. The study ID
key is contained in a password protected file on
password protected computers in a secure office area.
All questionnaires and biological specimens are stored
in locked cabinets/freezers in secure areas. Only study
team members have access to the identifying data col-
lected in this study.
Information from participants’ medical records is
obtained through linkage with the APH database. At the
study’s end, Alberta Health and Wellness will extract
the requested information from their database for our
study participants. Published results will report only
aggregate information and will not identify individual
participants. Participants will be notified of aggregated
study findings through the distribution of a study
summary.
Significance of The Study
The rate of preterm birth is on the rise in the developed
world. Alberta has the highest provincial preterm birth
rate in Canada, the causes of which remain unexplained.
The All Our Babies Cohort Study is strategically situated
to examine the environmental, medical and genetic fac-
tors impacting preterm birth in Alberta and seeks to
exploit their predictive properties for future clinical
screening of all pregnant women. Should gene expres-
sion patterns predictive of spontaneous preterm birth be
elucidated or gene-environment interactions protective
against or synergistic for a spontaneous preterm birth
outcome be discovered, the detailed phenotypic infor-
mation will inform validation endeavors. This could
potentially expedite the journey from basic science dis-
covery to clinical utility, a translation process which to
date has had limited success in the applications of
‘omics technologies in maternal-fetal newborn health. In
addition, this study will improve our understanding of
how social support and social services impact sponta-
neous preterm birth in Calgary.
The delivery of health services in the province of
Alberta is currently undergoing reorganization making
the assessment of women’s needs during pregnancy very
timely to inform service and program development and
change of healthcare policies. The comprehensive ques-
tionnaire data obtained from participants in the All Our
Babies Cohort Study combined with data from medical
records provides a concise record of local health prac-
tices and the impact of practice on maternal-fetal and
newborn health. The results of the study will provide
the opportunity to describe the mental health and psy-
chosocial characteristics of mothers living in Calgary as
well as estimates of the impact of these characteristics
on birth and the parenting experience. The All Our
Babies Cohort Study will also record women’sp r e n a t a l
care experience in Calgary and identify barriers and
facilitators to accessing prenatal care. In addition, the
information will enable evaluation of the relationships
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depression, parenting morale, anxiety, stress, social sup-
port, lifestyle choices such as smoking, drug use and
alcohol consumption, breastfeeding initiation, duration
and challenges and postpartum use of health care ser-
vices. Furthermore the research team is uniquely posi-
tioned to report directly to Alberta Health Services
stakeholders, ensuring knowledge gained from this
research is used to inform programs and practice.
Ethics
This study was approved by the following ethics review
boards: Health Research Ethics Board (University of
Alberta, Edmonton, Canada; Ethics ID 7515), Conjoint
Health Research Ethics Board (University of Calgary,
Calgary; Ethics ID 22128), Health Records Services
(Calgary; Ethics ID 2265), Child Health Research Office
(Calgary; Ethics ID #E-22128), and the Calgary Labora-
tory Services Ethics and Privacy Office (Calgary).
Participants are asked to provide verbal consent to
participate in the study over the phone at the time of
recruitment, and completion and return of the question-
naires signifies implied conse n t .A tt h et i m eo ft h ef i r s t
blood collection, participants are required to give signed
consent to the blood collections, access to medical
records and corresponding analyses. Participants are
given copies of the consent forms to which they pro-
vided informed consent over the phone and in writing.
Study Timeline
The All Our Babies Cohort Study began in September
2009. Participants are involved in the study for approxi-
mately one year’s time. It is anticipated that sample col-
lections will be completed by spring 2011, all
participants will have delivered their infant(s) by sum-
mer 2011 and data collection will be completed by fall
2011. Participants have been asked about their interest
in participating in follow-up studies, potentially allowing
for further research on early determinants of child and
adult health outcomes.
Discussion
Complex preterm phenotypes are determined by genetic,
physiological and environmental factors interacting at
the cellular, organ, systemic, and lifestyle levels. The All
Our Babies Cohort Study is gathering extensive detailed
data on the gene expression profiles, medical history,
lifestyle, demographics, physical and mental well-being,
and neighbourhoods of the participants to predict pre-
term birth in asymptomatic women. The integration of
these diverse data types will create an improved under-
standing of both maternal well-being in the perinatal
period and of the cascade of the pathophysiology of
preterm birth, the ultimate goal being improved mater-
nal-fetal-newborn health outcomes.
The All Our Babies Cohort Study is the optimal study
design to facilitate the integration of biological, medical
and social data. The research team, community labora-
tory service and provincial health service provider are
intimately partnered to facilitate multiple aspects of the
study process. Recruitment, biological sample collection,
and accessing medical record data are made possible by
the academic-clinical collaborations that are the founda-
tion of the All Our Babies Cohort Study. The imple-
mentation of this study protocol represents a successful
example of how academic-clinical partnerships can
increase efficiency in the research process, expediting
the generation of study findings by streamlining the
recruitment and collection phases of the study. Monthly
meetings, routine newsletters, local and provincial com-
mittee membership and established relationships with
key stakeholders, including program designers and deci-
sion makers, increase the likelihood of rapid translation
of research findings into policy and programs.
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